Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Panakes Partners
BioCentury | Dec 6, 2024
Emerging Company Profile
Disco: Mapping protein communities on cancer cell surfaces
German biotech has already mapped small cell lung cancer surface proteins, colorectal is next
BioCentury | Jan 18, 2024
Finance
VC roundup: Tr1X, Disco among the week’s launches
Plus: Comanche, Ratio, Advanced Medicine Partners and others raise cash
BioCentury | Nov 15, 2023
Finance
Nov. 14 Quick Takes: TPG leads $85M B round for ADC play MBrace
Plus: Nouscom raises €67.5M series C and more from Eyebio, Glox, Bayer and Ketabon
BioCentury | Jun 27, 2023
Product Development
June 27 Quick Takes: FDA denies Regeneron’s high-dose Eylea
Plus: Sanofi meets in atopic dermatitis and updates from Nkarta, Astraveus and more
BioCentury | Apr 17, 2023
Emerging Company Profile
Complement: taking on Apellis with a gene therapy for geographic atrophy
New target CR1 could shut down complement signaling more fully than Apellis’ C3-targeted therapy
BioCentury | Feb 18, 2023
Regulation
Feb. 17 Quick Takes: Apellis’ Syfovre first to market for geographic atrophy
Plus: Amid partnership talks, Madrigal also ‘open’ to M&A; and updates from Panakès, Aqilion-Merck KGaA, Pfizer, Merck & Co.
BioCentury | Jul 21, 2022
Finance
July 20 Quick Takes: Multiomics-driven cancer newco Auron raises $48M series A
Plus Section 32 leads BigHat’s $75M round; PTC gains first global approval of brain-infused gene therapy; and more
BioCentury | May 17, 2022
Finance
Indaco adds to Italian ecosystem with launch of first dedicated biotech fund
Firm raises €95M at first close, with €150M target for Italian biotechs
BioCentury | May 13, 2022
Finance
Italy solves its biotech chicken-and-egg problem
New funds and infrastructure to support company creation in Italy could in turn attract more investors and entrepreneurs
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
Items per page:
1 - 10 of 17